AusperBio

AusperBio is a clinical-stage biopharmaceutical company focused on transforming HBV treatment for a cure. They leverage their proprietary Med-Oligo™ ASO platform, which enhances current oligonucleotide therapeutics with strategically positioned chemical modifications, to achieve higher potency and better safety profiles. AusperBio is committed to advancing oligonucleotide therapeutics for a broad range of diseases including viral infections, metabolic conditions, genetic disorders, and immune diseases.

The company has made significant strides in its clinical development of AHB-137, its flagship ASO product targeting a highly conserved region shared among all HBV mRNA. AHB-137 has demonstrated best-in-class HBsAg reduction in preclinical studies and is currently advancing through a multiregional Phase I clinical trial in New Zealand, the United States, and China. With its unique and potent dual-action mechanism, AHB-137 holds immense potential to serve as a cornerstone for future combination therapies in pursuit of an HBV cure.

AusperBio is a clinical-stage biopharmaceutical company dedicated to transforming HBV treatment for a cure. They are driven by a mission to advance oligonucleotide and targeted delivery technologies to develop transformative therapies for a wide range of diseases, including viral infections, metabolic conditions, genetic disorders, and immune diseases.

AusperBio promotes a culture focused on innovation, collaboration, and a passion for improving patient lives. Their website emphasizes a dedication to developing transformative therapies and advancing oligonucleotide technology, suggesting a fast-paced and ambitious environment where employees are encouraged to think outside the box and contribute to groundbreaking research. The company's commitment to global impact and its impressive milestones also point towards a culture that values teamwork, perseverance, and a shared sense of purpose in tackling complex medical challenges.